Among AITL and PTCL-NOS patients, the ORR in patients treated with ADCETRIS plus CHP was independent of the level of CD30 expression.
The duration of complete response was not associated with CD30 expression level for patients with AITL or PTCL-NOS.
Twenty patients with refractory or early relapsed ALCL received allo-HSCT and PFS at 3 years after allo-HSCT was 75% [+ or -] 10%. Forty-five patients registered in the European Group for Blood and Marrow Transplantation with AITL were treated with allo-HSCT, and the clinical outcome is encouraging.
National Comprehensive Cancer Network (NCCN) guidelines recommend that if patients with primary refractory or relapsed PTCL-NOS, ALK-negative ALCL, AITL, or enteropathy-associated T-cell lymphoma had intention to transplantation, allo-HSCT should be considered.
Epstein-Barr virus (EBV) is estimated to be present in 80-95% of AITL
Pathological features favouring AITL
include prominent vascularisation by arborising venules, expansion of follicular dendritic cell networks, and the identification of CD10 as a phenotypic marker of neoplastic T-cells.
We presently report on a T-cell lymphoma, most consistent with angioimmunoblastic T-cell lymphoma (AITL
) [6, 7], occurring in an 80-year-old woman's inguinal lymph node.
Profiling of ALK+ ALCL and ALK- ALCL by The International T-Cell Lymphoma Project, and comparison with AITL
, adult T-cell leukemia/lymphoma, and PTCL-NOS, revealed that ALK+ ALCL could be separated from these entities at the molecular level.
Skin Site Diagnosis Stage 32 Left forearm NKTCL IV 33 Right popliteal fossa NKTCL IV 34 Right forearm NKTCL IV 35 Bilateral lower legs NKTCL IV 36 Left lower leg NKTCL IV 37 Leg AITL
IV 38 Right foot AITL
IV 39 Right upper arm AITL
IV 40 Bilateral upper limbs AITL
IV 41 Trunk and limbs AITL
IV 42 Right inguinal ALCL II 43 Multiple sites ALCL IV 44 Back PTCL III 45 Multiple sites PTCL IV 46 Trunk PTCL II 47 Multiple sites T-PLL IV 48 Multiple sites BPDC IV 49 Right forearm DLBCL IV 50 Left leg DLBCL IV 51 Right thigh DLBCL IV 52 Right thigh FL IV 53 Right scalp FL IV 54 Anus BL II 55 Scalp CLL/SLL IV 56 Left breast Small B-cell IV lymphoma, unclassified Case No.
The patent includes multiple claims directed to the use of tipifarnib as a method of treating patients with angioimmunoblastic T-cell lymphoma, or AITL
, an aggressive form of T-cell lymphoma.